Bupropion for the Treatment of Methamphetamine Dependence - 1

This study has been completed.

First Received: September 18, 2003 Last Updated: July 21, 2008 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00069251

Purpose

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Condition	Intervention	Phase
Amphetamine-Related Disorders	Drug: Bupropion	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Bupropion for the Treatment of Methamphetamine Dependence

Resource links provided by NLM:

MedlinePlus related topics: Methamphetamine

Drug Information available for: Methamphetamine hydrochloride Bupropion hydrochloride Bupropion Amphetamine Methamphetamine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Severity addiction
Methamphetamine use

Estimated Enrollment:	150
Study Start Date:	July 2003
Estimated Study Completion Date:	June 2005

Detailed Description:

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
Subject must be willing to comply with study procedures.
Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
Be able to comply with protocol requirements

Exclusion Criteria:

Please contact site for more information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00069251

Locations

United States, California
South Bay Treatment Center
San Diego, California, United States, 92105
Matrix Institute on Addictions
Costa Mesa, California, United States, 92627
United States, Hawaii
Pacific Addiction Research Center
Honolulu, Hawaii, United States, 96813
United States, Iowa
Powell Chemical Dependency Center
Des Moines, Iowa, United States, 50316
United States, Missouri
University of Missouri - Kansas City
Kansas City, Missouri, United States, 64108

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Richard Rawson, Ph.D.

University of California, Los Angeles

More Information

No publications provided

Study ID Numbers:	NIDA-CTO-0008-1
Study First Received:	September 18, 2003
Last Updated:	July 21, 2008
ClinicalTrials.gov Identifier:	NCT00069251 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs
Disorders of Environmental Origin
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Antidepressive Agents, Second-Generation

Antidepressive Agents
Sympathomimetics
Central Nervous System Stimulants
Pharmacologic Actions
Methamphetamine
Autonomic Agents
Amphetamine-Related Disorders
Bupropion
Dopamine Agents
Amphetamine
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 27, 2009